Archive
408 releases
Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right…
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year
Achieves 30% Revenue Growth Year-Over-Year
Cboe Global Markets, Inc. (Cboe: CBOE), a leading global markets operator and pioneer in equity and index derivatives, today reported October trading…
MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that it expects to report financial results on Tuesday, November 24,…
Reports a 32% increase in operating income and consistent year-over-year revenue and Adjusted EBITDA1
Third Quarter Pre-Tax Income of $116 million
Three-Year Contract Delivers Largest Wage Increase in More Than 25 Years CITY OF INDUSTRY, Calif., Nov. 4, 2026 — 220 workers at Ecobat, represented…
Russel Metals Inc. (TSX: RUS) announces financial results for three months ended September 30, 2026. Record Quarterly Revenues, Adjusted EBITDA and…
Third Quarter 2026 Net Income of $175.0 million or $0.85 per Diluted Share Third Quarter 2026 Adjusted Net Operating Income (Non-GAAP) of $174.7…
Delivered Third Quarter Net Sales of $147.6 Million, a 16.5% Increase Year-Over-Year
Grew total revenue to $151.8 million and testing revenue to $146.4 million, representing 15% year-over-year growth
Company's first-of-a-kind intelligent imaging system aims to expand patient access, streamline high-quality cardiac care, and establish the…
Victory Capital Reports Strong Third Quarter 2026 Results, Highlighted by Record Gross Sales and Net Flows
Launched Niagen™ Plus Niagen™ Liquid At-Home Injections
Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
